Absci utilizes a generative AI-driven Integrated Drug Creation platform that combines AI modeling with scalable wet lab validation to design and optimize biologics for therapeutic applications. This approach significantly reduces the time from drug conception to clinical candidates, enabling the screening of billions of cells weekly and accelerating the development of effective treatments for patients.

AI Proteins designs de novo miniprotein medicines engineered from first principles for precise therapeutic function. This next-generation biologic modality offers high control over selectivity, stability, and pharmacokinetics, minimizing off-target effects and unwanted immune responses. The platform enables the rapid synthesis and validation of potent, programmable, and safe treatments tailored to specific patient needs.

EnClear Therapies utilizes its proprietary EnTrega CSF Platform to deliver precision dosing of therapeutics directly to the central nervous system, minimizing severe side effects and peripheral toxicity. The company focuses on treating neuro-oncology and expanding into neurodegenerative, lysosomal storage, and autoimmune diseases, addressing the critical need for effective CNS disease management.

Mammoth Biosciences develops CRISPR-Cas-based gene editing therapeutics and diagnostics to enable precise in vivo applications for serious diseases and molecular detection. Their technology addresses the challenges of gene delivery and expands testing capabilities, providing permanent solutions for unmet medical needs.

This clinical-stage biotechnology company utilizes machine learning to enhance the design and development of peptide therapeutics, focusing on precision engineering. Their lead candidate, PLG0206, is a broad-spectrum anti-infective currently in clinical trials for treating prosthetic joint infections, a condition with significant treatment challenges.

Quthero develops a bioengineered wound management gel utilizing its proprietary Q-peptide technology, derived from Angiopoietin-1, to enhance cell migration and collagen deposition for faster healing. This gel effectively reduces inflammation and improves skin quality in post-aesthetic procedures, addressing the need for efficient wound care in dermatology.

Sciphermedicine is a company whose specific product offerings, technology, and target market are not publicly detailed.

Valo Health’s Opal Computational Platform unifies electronic health records, multi‑omics, proteomics, and imaging data in a cloud‑native environment and applies scalable machine‑learning models to predict target relevance, safety, and efficacy. The platform enables virtual patient cohorts, in‑silico compound screening, and API‑driven integration with existing R&D systems, accelerating hypothesis testing and decision cycles for pharmaceutical R&D, biotech, and CRO teams.